Clinical Trial

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy participants.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-06-09 -> 2026-11-07 2026-08-13
minor Completion pushed: 2026-06-15 -> 2026-11-07 2026-08-13
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07446400
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Healthy Volunteers
Enrollment 48 participants
Start Date 2026-03-31
Primary Completion 2026-11-07 (estimated)
Study Completion 2026-11-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-12